ENSCHealthcare · Biotechnology

ENSC Stock Forecast: Ensysce Biosciences, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026

$0.37

−1.93% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 41 of 100 as at 22 Aug 2026 — in the lower half.

Market cap

$7.3M

Ticker Nerd rank

41 / 100

Median analyst target

$8.25

Analysts covering

Total return, dividends reinvested

−7.4%

+29.5%

YTD

−59.7%

−82.1%

From 52W high

−85.6%

From 52W low

+47.6%

$0.25

$2.57

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

ENSC stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Ensysce Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026

41 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Revisions

Accruals

Issuance

Value

Growth

Momentum

Volatility

Quality

Size (94): Smaller than most of the companies we track.

Quality (4): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ENSC stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ENSC, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Recent analyst actionsNewest first

Date	Firm	Action	Rating	Target
25 Sept 2023	HC Wainwright & Co.	Maintains	Buy	$9.00 → $7.00
3 July 2023	HC Wainwright & Co.	Initiates	Buy	—
17 Nov 2022	Lake Street	Maintains	Buy	$80 → $8.00
30 Nov 2021	Lake Street	Initiates	Buy	$4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ENSC appears on the weeks it earns a place.

Estimates

ENSC analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year

Analysts raising

Analysts cutting

Fundamentals

Ensysce Biosciences, Inc. (ENSC) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: 0.0×
Price / sales: 1.6×
Price / book: −3.8×
EV / EBITDA: −0.6×

Growth & margins

Revenue growth (YoY): −15.1%
Earnings growth (YoY): —
Gross margin: —
Operating margin: −221.3%
Net margin: −280.5%

Returns & dividend

Return on equity: −1295.1%
Return on assets: −185.5%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

ENSC vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology

Company	Market cap	TKN rank
ENSCEnsysce Biosciences, Inc.	$7.3M	41
XCURExicure, Inc.	$7.3M	46
CURXCuranex Pharmaceuticals, Inc.	$7.4M	5
ALZNAlzamend Neuro, Inc.	$7.5M	34
BOLTBolt Biotherapeutics, Inc.	$7.0M	73
NIKINiki Biosolutions, Inc.	$7.0M	12
LIMNLiminatus Pharma, Inc.	$6.9M	10

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Ensysce Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ENSC news & analysis

Ensysce Biosciences to Showcase "A New Era in Pain Therapeutics" at PAINWeek 2026 Symposium

Accesswire · 20 Aug 2026positive

Ensysce Biosciences announced it will host an educational symposium titled "A New Era in Pain Therapeutics" at PAINWeek 2026. The symposium will present a vision for the future of pain management, highlighting a first-in-class neural reset approach and a novel chemical safety switch technology for severe pain and Complex Regional Pain Syndrome (CRPS).

Why it matters — The announcement gives ENSC watchers a look at the company's upcoming pipeline innovations and planned visibility at a major pain-care conference.

Ensysce Biosciences, Inc. (ENSC) Discusses Acquisition of Cy Biopharma and Private Placement Financing Prepared Remarks Transcript

Seeking Alpha · 18 Aug 2026neutral

Ensysce Biosciences, Inc. (ENSC) released a prepared remarks transcript discussing its acquisition of Cy Biopharma and a private placement financing arrangement. The transcript covers the company's statements on these corporate actions.

Why it matters — ENSC watchers would care because the acquisition of Cy Biopharma and the private placement financing could affect the company's business scope and capital position.

Ensysce Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Accesswire · 13 Aug 2026positive

Ensysce Biosciences reported its second quarter 2026 financial results and announced the completed acquisition of Cy Biopharma, which added CY200 for Complex Regional Pain Syndrome and brought up to $77 million in new funding. The company will host a corporate update call on August 18, 2026.

Why it matters — An ENSC watcher would care because the acquisition of Cy Biopharma expands Ensysce's pipeline with a new therapy for Complex Regional Pain Syndrome and provides significant additional funding.

Ensysce Biosciences Announces Acquisition of Cy Biopharma and up to $77 Million Private Financing

Accesswire · 6 Aug 2026positive

Ensysce Biosciences completed its acquisition of Cy Biopharma, a privately held clinical-stage company developing neuroplastogenic therapies focused on complex pain, including a therapy with U.S. FDA Orphan Drug Designation for Complex Regional Pain Syndrome. Concurrently, Ensysce entered into a private placement financing expected to bring gross proceeds of about $21.5 million at initial close, plus $17.1 million in cash from Cy Biopharma's pre-acquisition convertible note financing, with up to $38.6 million more upon a clinical trial milestone; pro forma cash is expected to fund CY200 through Phase 2 proof-of-concept data and into registrational development.

Why it matters — The acquisition adds a clinical-stage neuroplastogenic pain therapy to Ensysce's pipeline and provides financing expected to fund CY200's development through Phase 2 proof-of-concept and registrational work.

FAQ

Frequently asked questions about ENSC stock

How does Ticker Nerd's model rank ENSC?

As at 22 Aug 2026, Ensysce Biosciences, Inc. ranks 41 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (94 of 100).

What is the ENSC stock forecast for 2030?

No analyst covering Ensysce Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ENSC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8.25 to $8.25 over the next 12 months.

How has ENSC stock performed over the past year?

Ensysce Biosciences, Inc. returned -82.1% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Ensysce Biosciences, Inc. do?

Ensysce Biosciences Inc. is a clinical-stage pharmaceutical company developing prescription therapeutics for severe pain and central nervous system conditions, including ADHD and opioid use disorder.

What is the latest news on ENSC?

The most recent item we track (Accesswire, 20 Aug 2026): "Ensysce Biosciences to Showcase "A New Era in Pain Therapeutics" at PAINWeek 2026 Symposium". Ensysce Biosciences announced it will host an educational symposium titled "A New Era in Pain Therapeutics" at PAINWeek 2026. The symposium will present a vision for the future of pain management, highlighting a first-in-class neural reset approach and a novel chemical safety switch technology for severe pain and Complex Regional Pain Syndrome (CRPS).

Company

About Ensysce Biosciences, Inc.

Ensysce Biosciences Inc. is a clinical-stage pharmaceutical company developing prescription therapeutics for severe pain and central nervous system conditions, including ADHD and opioid use disorder. It leverages two proprietary prodrug platforms: TAAP™ (Trypsin-Activated Abuse Protection), which modifies active ingredients like oxycodone or amphetamine to remain inactive until exposed to trypsin in the small intestine, deterring tampering, injection, snorting, or chewing; and MPAR® (Multi-Pill Abuse Resistance), which incorporates a controlled-release trypsin inhibitor to limit active drug release in overdose scenarios, providing built-in protection. Lead programs include PF614, a TAAP™ extended-release oxycodone analogue in Phase 3 trials for post-surgical pain; PF614-MPAR, combining both platforms with FDA Breakthrough Therapy designation; PF8026 and PF8001 for ADHD; and PF9001 for opioid use disorder. These innovations aim to deliver effective analgesia and therapies while minimizing abuse, dependence, and overdose risks. Headquartered in La Jolla, California, Ensysce Biosciences Inc. operates in the pharmaceutical preparation manufacturing sector, focusing on tamper-resistant oral medications.

CEO Dr. D. Lynn Kirkpatrick Ph.D. · 8 employees · United States · https://www.ensysce.com